Evidence map›Paper›PMID 27600338›Full record

ReviewMicroarrays (Basel, Switzerland)2014

Identification of New Players in Hepatocarcinogenesis: Limits and Opportunities of Using Tissue Microarray (TMA).

Luca Quagliata, Manuel Schlageter, Cristina Quintavalle, Luigi Tornillo, Luigi M Terracciano

Abstract readReview
In one paragraph

Review in Microarrays (Basel, Switzerland), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. SpOT the Correct Tissue Every Time in Multi-tissue Blocks.Journal of visualized experiments : JoVE · 2015
    Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Luca QuagliataMolecular Pathology Division, Institute of Pathology, University Hospital of Basel, CH-4031 Basel, Switzerland. luca.quagliata@usb.ch.
Manuel SchlageterMolecular Pathology Division, Institute of Pathology, University Hospital of Basel, CH-4031 Basel, Switzerland. Manuel.Schlageter@usb.ch.
Cristina QuintavalleMolecular Pathology Division, Institute of Pathology, University Hospital of Basel, CH-4031 Basel, Switzerland. cristina.quintavalle@usb.ch.
Luigi TornilloMolecular Pathology Division, Institute of Pathology, University Hospital of Basel, CH-4031 Basel, Switzerland. luigi.tornillo@usb.ch.
Luigi M TerraccianoMolecular Pathology Division, Institute of Pathology, University Hospital of Basel, CH-4031 Basel, Switzerland. lterracciano@uhbs.ch.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liver tumours are among the leading causes of cancer-related death worldwide and hepatocellular carcinoma (HCC) accounts for the vast majority of liver tumours. When detected at an early stage of disease, patients might still be eligible for surgical-based curative treatments. However, currently only small portion of HCC affected patients are diagnosed at an early stage. For late stage HCC no treatment option exists beside the multi-tyrosine kinase inhibitor Sorafenib. Thus new molecular targets and treatment options for HCC are urgently needed. Nevertheless, despite some improvements in diagnosis and patient management, the biology of liver tumour remains inadequately understood, mainly because these tumours have shown to harbour a highly complex genomic landscape. In addition, one major obstacle delaying the identification of new molecular targets in biomedical research is the necessity to validate them using a large collection of tissue specimens. Tissue microarray (TMA) technology allows the prompt molecular profiling of multiple tissue specimens and is therefore ideal to analyze presumptive candidate biomarkers in a fast an effective manner. The use of TMA has substantial benefits over standard techniques and represents a significant advancement in molecular pathology. For example, TMA technology reduces laboratory work, offers a high level of experimental uniformity and provides a judicious use of precious tissue. On the other hand, one potential limitation of using TMA is that the small cores sampled may not be representative of whole tumors. This issue is very critical in particularly heterogeneous cancers such as HCC. For liver focused studies, it is ideal to evaluate the staining patters of a determined marker over the structure of an entire acinus and to define staining in as many as possible anatomical regions. In this review we analyze the limits and opportunities offered by the usage of TMA technology in HCC research. In summary, TMA has revolutionized the histopathological analysis and will be of great help to further advance the knowledge in the field of hepatocarcinogenesis research.

Indexed as

Hepatocellular carcinomaIHCliverTMA

Identifiers

PMID27600338
PMCPMC5003443

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.